Eur Rev Med Pharmacol Sci 2023; 27 (13): 6301-6318
DOI: 10.26355/eurrev_202307_32990

Comparison impact of cigarettes and e-cigs as lung cancer risk inductor: a narrative review

X.A. Abelia, R. Lesmana, H. Goenawan, R. Abdulah, M.I. Barliana

Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia. melisa.barliana@unpad.ac.id


Smoking cigarettes contributes to lung cancer progression and the development of other respiratory diseases. E-cigs are increasingly being offered to mitigate the harmful effects of traditional cigarettes and eventually for smoke cessation. Because e-cigs do not burn tobacco, it stands to reason that vaping e-liquid is less harmful than inhaling cigarette smoke. This study critically assessed the underlying biological effects of cigarettes and e-Cigs. We searched PubMed databases to elucidate the fundamental, potentially carcinogenic, molecular pathways and the possible effects of cigarettes and e-cigs products on lung cancer progression.

Cigarette smoke leads to chronic obstructive pulmonary disease (COPD), while e-cigs have contributed to lung injury. Cigarette smoke and e-cigs increase proinflammatory cytokine expression in cells and affect protein regulation, leading to an increased lung cancer risk.

E-cigs are quickly gaining popularity among consumers. Vaping-related diseases and deaths have attracted attention on a global scale. Excessive nicotine levels in e-liquid have the potential to cause severe toxicity, which can lead to neurological and brain damage and respiratory failure, as well as death. Thus, the toxic effects of e-cigs aerosol exposure are essentially identical to that caused by combustible cigarette smoking.

Free PDF Download

To cite this article

X.A. Abelia, R. Lesmana, H. Goenawan, R. Abdulah, M.I. Barliana
Comparison impact of cigarettes and e-cigs as lung cancer risk inductor: a narrative review

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 13
Pages: 6301-6318
DOI: 10.26355/eurrev_202307_32990